# EU Approves Incyte's Povofortay for Adults With Limited Anti-TNF Options

By Riza Dagoc

Canonical URL: https://www.tokenpost.com/news/regulation/59526
Published: 2026-11-17T15:11:26.000Z
Updated: 2026-11-17T15:11:26.000Z
Section: Regulation

> The authorization covers active moderate to severe hidradenitis suppurativa. U.S. regulators are reviewing an application for the same drug.

The European Commission approved Incyte's Povofortay for adults with active moderate to severe hidradenitis suppurativa who have limited anti-TNF treatment options, authorizing the drug in the European Union while a U.S. application remains under review.

The Nov. 12 authorization covers adults whose response to anti-TNF therapy was inadequate, who cannot tolerate it or for whom it is contraindicated. Hidradenitis suppurativa is a chronic inflammatory skin condition. Povofortay (povorcitinib) is a once-daily pill approved in 45 mg and 75 mg tablet strengths.

Incyte's Phase 3 STOP-HS1 and STOP-HS2 trials both met their primary goal at Week 12. More patients taking either dose reached the HiSCR50 endpoint than those taking a placebo. The endpoint required at least a 50% reduction in abscesses and inflammatory nodules, with no increase in abscesses or draining tunnels.

The U.S. Food and Drug Administration is reviewing an application for Povofortay supported by the same two trials.


